Left to Right: Eiji Yoshihara, Jinhyuk Choi, Shudi Wang, Yu Hamba, Harvey Perez, Clarissa Tacto, and Fritz Cayabyab
Human pluripotent stem cell–derived islets hold great promise as a functional cure for diabetes. However, the absence of reliable markers to distinguish functionally competent islets has made their use in therapy somewhat of a gamble.
Authored by President and CEO Joe W. Ramos, PhD
Last Wednesday, I was honored to address our incredible community during my welcome event at The Lundquist
Institute (TLI). As I stood among colleagues, community leaders, and longtime supporters, I was struck by the
sense of possibility in the room. It was a powerful evening of shared reflection and bold vision, and the perfect
moment to start a conversation I plan to carry forward daily in this role: where we’ve been, what we’re facing, and
most importantly, where we can go, together.
Join us on Wednesday, May 7 as we celebrate a new chapter for The Lundquist Institute under the leadership of CEO Joe W. Ramos, PhD.
We’re excited to invite you to Charting the Future of TLI with CEO Joe W. Ramos, PhD on Wednesday, May 7, at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
Join us for a Welcome Reception from 7:30 to 9:00 p.m. as we celebrate a new chapter for The Lundquist Institute under the leadership of CEO Joe W. Ramos, PhD. This special evening will bring faculty, staff, and supporters together to meet our new CEO and connect around our shared mission.
Just before his first birthday, Christian de Virgilio, MD, was diagnosed with infantile hemolytic uremic syndrome – a condition where a baby’s red blood cells break down rapidly and renal failure sets in as a result of a life-threatening E. coli infection. In need of medical attention, his parents had to decide if they would rely on the public hospital that accepted their health insurance or pay upfront and out-of-pocket for aid at the nearby private hospital in their hometown of Cordoba, Argentina.
Top Row: Yiyou Gu, Teclegiorgis Gebremariam, Ashraf Ibrahim, and Abdullah Alqarihi
Bottom Row: Sondus Alkhazraji, Eman Youssef, and Ashley Barbarino
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is thrilled to announce that Dr. Marisela Montoya, Ed.D., IBCLC, Executive Director of the South Los Angeles Health Projects (SLAHP), has been recognized by the Los Angeles County Commission for Women "Woman of the Year" Award recipient.
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) extends its heartfelt thanks to Dan Rosenfeld for his invaluable contributions and years of dedicated service at the Institute. Dan is ‘Chair Emeritus,’ having served on our Board of Directors for over a decade.
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is pleased to announce the appointment of Joe W. Ramos, PhD, as its new President and Chief Executive Officer, effective January 21, 2025. Dr. Ramos, a renowned cancer researcher and experienced scientific leader, brings decades of expertise in advancing biomedical innovation and fostering collaborative research initiatives.
Join us at Legends 2024 as we celebrate over 70 years of groundbreaking biomedical innovation at The Lundquist Institute and honor our 2024 Legends — Sharon Adler, MD; Amy Kaji, MD, PhD (honored posthumously); and Michael Yeaman, PhD — with prestigious lifetime achievement awards recognizing their significant and enduring contributions to scientific and me
Dr. Shakti Singh from the Division of Infectious Diseases has been awarded the prestigious five-year K01 Grant for their innovative research on the deadly fungal pathogen Candida auris. This five-year grant, provided by the National Institutes of Health (NIH), supports Dr. Singh’s cutting-edge work, which aims to unravel the complex mechanisms of C.